Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.

¹ From the Department of Neuroinflammation (W.B., O.C.), Queen Square MS Centre, UCL Queen Square Institute of Neurology, London, United Kingdom; Department of Neurology (D.B.), Oregon Health & Science University, Portland, OR; Menzies Health Institute Queensland (S.B.), Griffith University, Gold Coast Campus, Queensland, Australia; Department of Neurology (J.K.), Amsterdam University Medical Center, Amsterdam, the Netherlands; and University College London Hospitals NIHR Biomedical Research Centre (O.C.), London, United Kingdom. [email protected].
² From the Department of Neuroinflammation (W.B., O.C.), Queen Square MS Centre, UCL Queen Square Institute of Neurology, London, United Kingdom; Department of Neurology (D.B.), Oregon Health & Science University, Portland, OR; Menzies Health Institute Queensland (S.B.), Griffith University, Gold Coast Campus, Queensland, Australia; Department of Neurology (J.K.), Amsterdam University Medical Center, Amsterdam, the Netherlands; and University College London Hospitals NIHR Biomedical Research Centre (O.C.), London, United Kingdom.

No abstract available

MeSH terms